Member Info for denby69

YOU Cant see the wood for the trees can you stevo999 the share holders are getting diluted by 1/5 we will own less and the out come the share price goes down again lol

stevo999 well answer my take on things :-P

So EUA are selling, Rosgeo JV for say 20 million $ and we are getting our holding diluted bu a fifth and eua keep the money to prove other assets am I right ??? please correct me if i am wrong.

BOD please an rns about funding plz

mmmmmmmm guess this is more debt ??

what you keeping horses now ?

stable ?

Only way is up now ?

https://www.reuters.com/business/more-chinese-provinces-issue-bans-cryptomining-2021-06-11/

:-) you missed ABC to day nice little rise ?

lol porker :-)

Lets hope the coe ****s this up give her the boot she does not care about share holders

I did not make up what I posted it is what was reported I just thought going what i had seen that it might effect the share price as litigation does not come cheep,
Please do not shoot the messenger ?

:-P hehehe

LOL could not resist it after you said about street girls yesterday :-)

PFC the firm have not done anything wrong so forget the firm and a big fine they will drop it soon

you not picked up a client and bedded him her I read last night that when the split happens the consumer Healthcare will be loaded with 4 x the debt it makes in yearly profit ?? what do you think ??

morning :-i

Its amazing, when you want to get this S P up it goes down and now i want it to go down it goes up sods law lol

bonkers99 ,

Big bad resistance @38k

TR64,

THIS is what I was referring to in regards to the gsk share price I just thought that this might cost GSK money if ASTRA ZENECA WON ???????
AstraZeneca has filed a suit against GSK in the U.K., demanding a bigger share of sales from the Tesaro cancer med Zejula, The Times reports. If AZ succeeds, the lawsuit could potentially net the company hundreds of millions of pounds, the newspaper reported, citing a source.

Tesaro developed Zejula, a PARP inhibitor, with help from technology licensed from AZ, which sells the rival drug Lynparza. In its suit, AZ accuses GSK of breaching the original Tesaro licensing agreement, which GSK denies, according to the newspaper.

As the first-to-market PARP drug, AZ’s Merck-partnered Lynparza is the clear leader in the field. The drug generated $543 million for AZ in the first quarter of 2021, compared with about $124 million for GSK's Tesaro.

Last year, Lynparza scored an FDA nod to be used alongside Roche’s Avastin for ovarian cancer patients who’ve responded to one round of chemo regardless of their tumor's BRCA mutation status. It followed a similar nod by Zejula in the same first-line maintenance setting. But in a win for GSK, Zejula’s label covers a large subtype of the disease that Lynparza doesn’t have—tumors without homologous recombination deficiencies (HRD), which constitute about half of all ovarian cancer cases.

TR64,

This is what I was referring to in regards to the gsk share price I just thought that this might cost GSK money if ASTRA ZENECA WON ???????
AstraZeneca has filed a suit against GSK in the U.K., demanding a bigger share of sales from the Tesaro cancer med Zejula, The Times reports. If AZ succeeds, the lawsuit could potentially net the company hundreds of millions of pounds, the newspaper reported, citing a source.

Tesaro developed Zejula, a PARP inhibitor, with help from technology licensed from AZ, which sells the rival drug Lynparza. In its suit, AZ accuses GSK of breaching the original Tesaro licensing agreement, which GSK denies, according to the newspaper.

As the first-to-market PARP drug, AZ’s Merck-partnered Lynparza is the clear leader in the field. The drug generated $543 million for AZ in the first quarter of 2021, compared with about $124 million for GSK's Tesaro.

Last year, Lynparza scored an FDA nod to be used alongside Roche’s Avastin for ovarian cancer patients who’ve responded to one round of chemo regardless of their tumor's BRCA mutation status. It followed a similar nod by Zejula in the same first-line maintenance setting. But in a win for GSK, Zejula’s label covers a large subtype of the disease that Lynparza doesn’t have—tumors without homologous recombination deficiencies (HRD), which constitute about half of all ovarian cancer cases.